NDUFAB1 and hepatocellular carcinoma: The meaningful improvements in OS, high objective response rates, and favorable toxicity profiles of IO agents versus sorafenib in patients with advanced HCC supported approval59, 60 for IO combinations in first‐line therapy, restricted to patients with good liver function (CP A), no active virus infection, and low risk of bleeding.16, 17